Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human GLP1R Antibodies:
anti-Mouse (Murine) GLP1R Antibodies:
anti-Rat (Rattus) GLP1R Antibodies:
Go to our pre-filtered search.
Human Polyclonal GLP1R Primary Antibody for DB, ICC - ABIN4314326
Kedees, Guz, Grigoryan, Teitelman: Functional activity of murine intestinal mucosal cells is regulated by the glucagon-like peptide-1 receptor. in Peptides 2013
Show all 6 references for ABIN4314326
Human Polyclonal GLP1R Primary Antibody for IF, ELISA - ABIN1535693
Thorens, Porret, Bühler, Deng, Morel, Widmann: Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. in Diabetes 1993
Show all 2 references for ABIN1535693
Human Polyclonal GLP1R Primary Antibody for IHC, IHC (p) - ABIN270557
Matveyenko, Dry, Cox, Moshtaghian, Gurlo, Galasso, Butler, Butler: Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. in Diabetes 2009
Show all 2 references for ABIN270557
Human Polyclonal GLP1R Primary Antibody for FACS, IF (p) - ABIN731333
Zhou, Yang, Xin, Li, Guo, Hu, Zhou, Zhang, Zhang, Han, Chen: Exendin-4 protects adipose-derived mesenchymal stem cells from apoptosis induced by hydrogen peroxide through the PI3K/Akt-Sfrp2 pathways. in Free radical biology & medicine 2014
Show all 2 references for ABIN731333
Human Monoclonal GLP1R Primary Antibody for FACS - ABIN4899829
Thompson, Stephens, Bain, Kanamarlapudi: Molecular Characterisation of Small Molecule Agonists Effect on the Human Glucagon Like Peptide-1 Receptor Internalisation. in PLoS ONE 2016
Role of cysteine 341 and arginine 348 of GLP-1 receptor in G-protein coupling.
GLP1-R may represent a novel target for treating bronchial hyperresponsiveness.
Our studies show that GLP-1R is widely expressed throughout the human hypothalamus. The decreased expression of GLP-1R in the PVN and IFN of T2DM patients may be related to the dysregulation of feeding behavior and glucose homeostasis in type 2 diabetes mellitus.
The effects of GLP-1 (show GCG Antibodies)-based therapies on blood glucose in type 2 diabetics are not mediated through microvascular responses.
In conclusion, exenatide significantly improves coronary endothelial function in patients with newly diagnosed type 2 diabetes. The effect may be mediated through activation of AMPK (show PRKAA1 Antibodies)/PI3K (show PIK3CA Antibodies)-Akt (show AKT1 Antibodies)/eNOS (show NOS3 Antibodies) pathway via a GLP-1R/cAMP-dependent mechanism.
A higher likelihood of attaining A1c goal levels were observed when a GLP-1R agonists was initiated.
Immunohistochemistry of human ileum tissues was performed in this study, which showed that TAS2R38 (show TAS2R38 Antibodies) was co-localized with glucagon-like peptide 1 (GLP-1 (show GCG Antibodies)) in enteroendocrine L-cells.
Data suggest that three conserved positively charged residues located at extracellular ends of transmembrane helices 3, 4 and 5 of GLP1R are essential for high affinity agonist binding and conformational transitions linked to pleiotropic effector coupling through stabilisation of extracellular domains.
The rate of homologous desensitization and internalization of the GLP-1R has been determined in a transgenic cell line system.
In the glucagon receptor (GCGR (show GCGR Antibodies)) and glucagon-like peptide-1 receptor (GLP-1R), the extracellular domain is required for signaling even when the hormone is covalently linked to the transmembrane domain.
In glucagon (show GCG Antibodies)-like peptide receptor (GLP-1R) expressing cells, small molecule agonists induced cAMP production but caused no intracellular Ca2 (show CA2 Antibodies)+ accumulation, ERK (show EPHB2 Antibodies) phosphorylation or hGLP-1R internalisation.
Enhanced beta-cell GLP-1R signaling contributes to improved glucose regulation after vertical sleeve gastrectomy by promoting increased glucose-stimulated insulin (show INS Antibodies) secretion.
Results suggest a detectable but only modest role for GLP-1R signaling in mediating the effects of Roux-en-Y gastric bypass and that this role is limited to its well-described action on glucose regulation.
Hypothalamic Glp1r is sufficient but not necessary for regulation of energy balance and glucose homeostasis.
Genetic deletion of both GLP-1 (show GCG Antibodies) and GIP (show GIP Antibodies) receptors reveals that they are required to maintain an adequate islet number in adulthood and to maintain normal beta cell responses to glucose.
present study provides critical insights regarding the nature by which GLP-1 (show GCG Antibodies) signaling controls reinforced behaviors and underscores the importance of both peripheral and central GLP-1R signaling for the regulation of addictive disorders.
CB1 (show CNR1 Antibodies) activation negatively impacts GLP-1R-mediated insulin (show INS Antibodies) secretion.
These differential effects of exogenous Glp1r in nondiabetic and diabetic mice suggest that downregulation of Glp1r might be required to slow the progression of beta-cell failure under diabetic conditions.
although endogenous GLP-1R signalling contributes to increased brown adipose tissue thermogenesis, this mechanism does not play a significant role in the food intake-independent body weight lowering effect of the GLP-1 (show GCG Antibodies) mimetic liraglutide in obese mice
GLP-1R is present in pancreatic acinar cells and that GLP-1 (show GCG Antibodies) can regulate secretion through its receptor and cAMP signaling pathway.
GLP1R is expressed in mouse retina. GLP-1R protein abundance was independent of the presence of diabetes.
induces insulin secretion\; mediates neuroendocrine signaling of feeding behavior\; mediates cardiovascular response and increased blood pressure
glucagon-like peptide 1 receptor
, glucagon-like peptide 1 receptor-like
, GLP-1 receptor
, pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1